| GenVec Announces Interim Survival Data In Pivotal Trial Of TNFerade™ In Locally Advanced Pancreatic Cancer |
| GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade™ (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.
11/20/2008
|
| Genetic Risk Factors May Tailor Prostate Cancer Screening Approaches |
| Men with a family history of prostate cancer and African-American men are particularly susceptible to the disease, with a twofold to sevenfold increased risk. Assessing risk in these populations has been difficult. "There have been years of effort to try to identify genes and genetic mutations associated with prostate cancer as there are for breast cancer," said Veda N. Giri, M.D.
11/18/2008
|
| Growing Number Of Young Prostate Cancer Patients Need 'sexual Rehabilitation' |
| Prostate cancer is being detected and treated at an earlier age, resulting in more cases of erectile dysfunction in younger men. While for many this is a temporary setback, for some it can take much longer and others will never recover their former capability. Dr Michael Lowy from Sydney Men's Health, said the result was a growing demand for "sexual rehabilitation" services, an evolving scientific and clinical branch of sexual medicine and urology.
11/18/2008
|
| Significantly Lower PSA Levels Discovered In Men Who Take Aspirin |
| The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is significantly associated with lower PSA levels, especially among men with prostate cancer, say researchers at Vanderbilt University. This large analysis known as the Nashville Men's Health Study included 1,277 participants referred to a urologist for a biopsy of their prostate. Approximately 46 percent of the men reported taking an NSAID, mostly aspirin (37 percent of all men).
11/18/2008
|
| Nymox Reports Positive New Results In 59 Week Study Of Drug For Enlarged Prostate |
| Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce positive new results from the Company's most recent study of NX-1207, its drug in development for benign prostatic hyperplasia (BPH). A total of 67 patients and controls in this multi-center U.S. study consisting of 92% of eligible patients were followed for an average of 59 weeks after a single administration of NX-1207. Of the patients given full dose NX-1207, 76.7% required no further treatment compared to 37.
11/17/2008
|
| Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System For Use In Prostate Surgeries |
| Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies, Inc., today announced that it has developed a pelvic cooling catheter system called UroCool(TM), which is designed to induce localized cooling during surgery for prostate cancer (radical prostatectomy). The new technology is being applied in collaboration with renowned prostate surgeon, Thomas E. Ahlering, M.D.
11/17/2008
|
| Cancer Treatment May Result In Bone Loss |
| New cross-Canada study in Journal of Clinical Oncology outlines risks A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss. In the online edition of the Journal of Clinical Oncology, the scientists explain how loss of bone mass might affect 46,000 people diagnosed with breast and prostate cancer each year* and place them at increased risk for osteoporosis and fractures.
11/16/2008
|
| New Findings Offer Fresh Hope To Men With Prostate Cancer That Has Returned After Attempted Cure |
| The link between the PSA (prostate-specific antigen) blood test and the detection of prostate cancer is well-established. In new findings released publicly for the first time today, Australian and New Zealand researchers have demonstrated how two serial measures of PSA can be used to accurately predict a patient's prognosis when prostate cancer returns after attempted cure.
11/16/2008
|
| Treatment Of Patients After Failed High Intensity Focused Ultrasound And Radiotherapy For Localized Prostate Cancer |
| UroToday.com - One of the international leaders in laparoscopic radical prostatectomy, Jens-Uwe Stozenburg from Leipzig, Germany and associates has reported on the use of salvage laparoscopic extra-peritoneal radical prostatectomy (EERPE) following failed high intensity focused ultrasound therapy (HIFU), external beam radiotherapy (ERBT) or brachytherapy.
11/16/2008
|
| Prevalence Of A Tertiary Gleason Grade And Its Impact On Adverse Histopathologic Parameters In A Contemporary Radical Prostatectomy Series |
| UroToday.com - Almost 40 years ago, Donald F. Gleason pioneered his well acknowledged grading system of prostate adenocarcinoma. In the ensuing years, the reliability of the Gleason system in predicting the outcomes of patients with prostate cancer (PCa) undergoing surgery, radiation therapy or surveillance has been proven in several single and multi-institutional studies. In its original version, the Gleason system considered only the two most predominant Gleason patterns.
11/15/2008
|
| The Influence Of Statin Medications On Prostate-specific Antigen Levels |
| UroToday.com - According to a report by Dr. Robert J. Hamilton and associates that appears in the November 5, 2008 issue of the Journal of the National Cancer Institute, statin use lowers PSA levels, and as a result may confound the detection of prostate cancer (CaP) in these patients. Statins are lipid-lowering agents in widespread use in the US. Several reports suggest that men on statins have a reduction in the risk of advanced CaP that ranges from 25% to 75%.
11/15/2008
|
| Robotic-Assisted Laparoscopic Radical Prostatectomy: Perioperative Outcomes Of 1500 Cases |
| UroToday.com - Consistent with a previous series of robotic-assisted laparoscopic radical prostatectomies (RALP) in over 2,500 patients, reported by Menon, et al., Dr. Vipul Patel presented his group's data on 1,500 RALP patients and confirmed the high-quality outcomes of this procedure. In the online version of the Journal of Endourology, Dr. Patel reported on 1,500 men on whom he performed transperitoneal RALP.
11/15/2008
|
| Androgen-Regulated And Highly Tumorigenic Human Prostate Cancer Cell Line Established From A Transplantable Primary CWR22 Tumor |
| UroToday.com - The molecular mechanisms underlying development of androgen-independent growth of prostate cancer are largely unknown, and no effective therapies for hormone-refractory prostate cancer exist at present.
11/15/2008
|
| Cancer Treatment May Result In Bone Loss - New Cross Canada Study |
| A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss. In the online edition of the American Society of Clinical Oncology, the scientists explain how loss of bone mass might affect 46,000 people diagnosed with breast and prostate cancer each year* and place them at increased risk for osteoporosis and fractures. "Our study also looked at possible medications that can reverse or halt bone loss," says Dr.
11/14/2008
|
| European Urology: Relationship Between Prostate Information And LUTS Evident |
| In the December issue of European Urology, Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial .
11/10/2008
|
